
AVXL Stock Forecast & Price Target
AVXL Analyst Ratings
Bulls say
Anavex Life Sciences is seen as a prospect for investors, as it engages in the development of precision medicine for neurodegenerative and neurodevelopmental diseases with high unmet need. The company has a strong pipeline, including ANAVEX 2-73 and ANAVEX 3-71, and continues to engage with the FDA and EMA on their regulatory pathway, reinforcing the belief that the U.S. remains the primary value driver. With clinical data showing potential for neuroprotection and convenience of administration, Anavex Life Sciences may have a strong chance of success, which is reflected in our $24.0 price target and use of a 30% discount rate in our valuation.
Bears say
Anavex Life Sciences is faced with a challenging future as the company expands into multiple indications beyond Alzheimer’s disease, including Parkinson’s disease and Rett syndrome. Their current valuation is impacted by lowered therapeutic success probabilities in the US and EU markets, supported by a discounted cash flow model, discounted earnings per share model and a sum-of-the-parts analysis.
This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
AVXL Analyst Forecast & Price Prediction
Start investing in AVXL
Order type
Buy in
Order amount
Est. shares
0 shares